Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 200-206

  Yui, Kunio ^a,b   Koshiba, Mamiko ^c   Nakamura, Shun ^c   Kobayashi, Yuji ^d  

^a Ashiya University   (Japan)

^b Sawa Hospital   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d SRL INC   (Japan)

Author keywords

Arachidonic acid; Autism spectrum disorders; Dietary unsaturated fatty acids; Docosahexaenoic acid; Social interaction

Indexed keywords

ARACHIDONIC ACID; ARAVITA; ASTAXANTHIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; PLACEBO; SUPEROXIDE DISMUTASE; TRANSFERRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CELL MATURATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; ENZYME BLOOD LEVEL; FATTY ACID BLOOD LEVEL; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; MEASUREMENT; NERVE CELL; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIGNAL TRANSDUCTION; SOCIAL ADAPTATION; SOCIAL DISABILITY; SUPPLEMENTATION; TREATMENT DURATION; UPREGULATION;

ADOLESCENT; ADULT; ARACHIDONIC ACID; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR DISORDERS; SUPEROXIDE DISMUTASE; TRANSFERRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857912269     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182485791     Document Type: Article

References (53)

1. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children and serious behavioral problems. N Engl J Med. 2002;347:314-321.
2. McDougle CJ, Scahill L, Aman MG, et al. Riseridone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on pediatric psychopharmacology. Am J Psychiatry. 2005;162:1142-1148. (Pubitemid 40770697)
3. Posey DL, Stigler KA, Erickso CA, et al. Antipsychotics in the treatment of autism. J Clin Invest. 2008;118:6-14.
4. West L, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care. 2009;23:75-89.
5. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633-641. (Pubitemid 28340352)
6. Hednmalm K, Guzey C, Dahl M-L, et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphism. J Clin Psychopharmacol. 2006;26:192-197. (Pubitemid 43740346)
7. Courchesne E, Pierce K, Schumann CM, et al. Mapping early brain development in autism. Neuron. 2007;56:399-413.
8. Kurlak LO, Stephenson TJ. Plausible explanations for effects of long-chain polyunsaturated fatty acids (LCPUFA) on neonates. Arch Dis Child Fetal Neonatal Ed. 1999;80:F148-F154. (Pubitemid 29122220)
9. Richardson AJ, Puri BK. A randomized double-blind, placebo- controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific leaning difficulties. Prog Neurobiopharmacol Psychiatry. 2002;26:233-239. (Pubitemid 34038049)
10. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001;65:1-7. (Pubitemid 32783435)
11. Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they a role in the pathophysiology of autism? Neuroendocrinol Lett. 2006:27:465-471. (Pubitemid 46043603)
12. Bell JD, Miller D, MacDonald DJ, et al. The fatty acid compositions of erythrocyte and plasma polar lipids in children with autism, developmental delay or typical developing controls and the effect of fish oil intake. Br J Nutr. 2010;103:1160-1167.
13. Johnson CR, Handen BL, Zimmer M, et al. Polyunsaturated fatty acid supplementation in young children with autism. J Dev Phys Disabil. 2010;22:1-10.
14. Politi P, Cena H, Comelli M, et al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res. 2008;39:682-685.
15. Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003;38:1007-1021. (Pubitemid 37444624)
16. Amminger GP, Berger GE, Schäfer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551-553. (Pubitemid 46185334)
17. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol. 2005;32:89-103. (Pubitemid 41113211)
18. Chen KC, Liu W-H, Chang L-S. Suppression of ERK signaling evokes autocrine Fas-mediated death in arachidonic acid-treated human chronic myeloid leukemia K562 cells. J Cell Physiol. 2009;222:625-634.
19. Birch EE, Garfield S, Hoffman DR, et al. A randomized controlled trial of early dietary supply of long-chain polysaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174-181. (Pubitemid 30145332)
20. Maekawa M, Takashima N, Matsumata M, et al. Arachidonic acid drives postnatal neurogenesis and elicits a beneficial effect on prepulse inhibition, a biological trait of psychiatric illness [published online ahead of print April 8, 2009]. PLos One. 2009;4:e5085.
21. Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord. 2011;41:545-554.
22. Heinrichs SC. Dietary U-3 fatty acid supplementation for optimizing neural structure and function. Mol Nutr Food Res. 2010;54:447-456.
23. Qian ZN, Li H, Sun H, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54:561-587. (Pubitemid 35351196)
24. Park S, Yoon SY, Kim K-E, et al. Interleukin-18 induces transferrin expression in breast cancer cell line MCF-7. Cancer Let. 2009;286:189-195.
25. Zhang Y, Zhang H-M, Shi Y, et al. Loss of manganese superoxide dismutase leads to abnormal growth and signal transduction in mouse embryonic fibroblasts. Free Radic Biol Med. 2010;49:1255-1262.
26. Yamakura F, Kawasaki H. Post-translational modifications of superoxide dismutase. Biochim Biophys Acta. 2010;1804:318-325
27. First M, Gibbon M, Spitzer RL, et al. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID, Version 2.0). New York, NY: New York State Psychiatric Institute, Biometrics Research Department; 1995.
28. Rutter M, Le Couteur A, Lord C. Autism Diagnostic Inventory-Revised. Los Angeles, CA: Western Psychological Services; 2003.
29. Wechsler D. Wechsler Intelligence Scale for Children-Revised Manual. New York, NY: The Psychological Corporation; 1974.
30. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. San Antonio, TX: The Psychological Corporation; 1981.
31. Noterdaeme M, Wriedt E, Höhne C. Asperger's syndrome and high-functioning autism: language, motor and cognitive profiles. Eur Child Adolesc Psychiatry. 2010;19:475-481.
32. Aman MG, Burrow WH, Wolford PL. Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. Am J Ment Retard. 1995;100:283-292.
33. Aman MG, Singh NN. Aberrant Behavior Checklist-Community: Supplementary Manual. East Aurona, NY: Slosson Educational Publications; 2006.
34. Constantino JN. The Social Responsiveness Scale. Los Angeles, CA: Western Psychological Services; 2002.
35. Constantino JN, Todd RD. Intergenerational transmission of subthreshold autistic traits in the general population. Biol Psychiatry. 2005:57:655-660. (Pubitemid 40409704)
36. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2009;35:990-998.
37. Hamazaki K, Itomura M, Hamazaki T, et al. Effects of cooking plant oils on recurrent aphthous stomatitis: a randomized, placebo-controlled, double-blind trial. Nutrition. 2006;22:534-536.
38. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci. 1959;37:911-917.
39. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem. 1984;142:290-296. (Pubitemid 15177262)
40. Norusis MJ. PASW Statistics 18 Advanced Statistical Procedures. Chicago, IL: SPSS Inc; 2010.
41. Bangalore S, Messerli FH. Of statistical significance: "trends" toward significance and optimism bias. J Am Coll Cardiol. 2006;48:1471. (Pubitemid 44436812)
42. Medical Dictionary for Regulatory Activities (MedDRA). Version 13.1. Reston, VA: MedDRA MSSO; 2007.
43. Pruett JR, LaMacchia A, Hoertel S, et al. Social and non-social cueing of visuospatial attention in autism and typical development. J Autism Dev Diord. 2011;41:715-731.
44. Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents withAD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17:1-8.
45. Young GS, Conquer JA, Thoma R. Effect of randomized supplementation with high dose olive, flax or fish oil on serum phospholipid fatty acid levels in adults with attention deficit hyperactivity disorder. Reprod Nutr Dev. 2005;45:549-558. (Pubitemid 41511881)
46. Yehuda S, Rabinovitz S, Carasso RL, et al. Fatty acids and brain peptides. Peptides. 1998;19:407-419. (Pubitemid 28097944)
47. Sublette ME, Russ MJ, Smoth GS. Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord. 2004;6:95-105. (Pubitemid 38443562)
48. Schonfeld E, Yasharel B, Yavin E, et al. Docosahexaenoic acid enhances iron uptake by modulation iron transporters and accelerates apoptotic death in PC12 cells. Neurochem Res. 2007;32:1673-1684. (Pubitemid 47428861)
49. Zhang W, Wang Y, Chen C-W, et al. The positive feedback role of arachidonic acid in the platelet-derived growth factor-induced signaling in lens epithelial cells. Mol Vis. 2006;12:821-831. (Pubitemid 44132600)
50. Ahmed M, Neville MJ, Edelmann MJ, et al. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity. 2009;18:27-34.
51. Lina BAR, Wolterbeek APM, Suw Y, et al. Subchronic (13-week) oral toxicity study, preceded by an in utero exposure phase, with arachidonate-enriched triglyceride oil (SUNTAGA40A) in rats. Food Chem Toxicol. 2006;44:326-335. (Pubitemid 41779432)
52. Nisha A, Muthukumar SP, Venkateswaran G. Safety evaluation of arachidonic acid rich Mortierella alpina biomass in albino rats: a subchronic study. Regul Toxicol Pharmacol. 2006;53:186-194.
53. Gibson RA, Barclay D, Marshall D, et al. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomized controlled trial. Br J Nutr. 2009;101:1706-1713.